Actualizado 28/04/2006 09:34
- Comunicado -

Herceptin Receives Positive Opinion in Europe for Early Use in HER2-Positive Breast Cancer (y 2)

[iv] Romond, E., Perez, E. et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2 Positive Breast Cancer. New England Journal of Medicine 353:16 2005.

[v] Collaborative partners for the HERA study include: Roche, BIG and its affiliated collaborative groups, plus non-affiliated collaborative groups, and independent sites.

[vi] World Health Organization, 2000.

[vii] Extra JM, Cognetti F, Maraninchi D et al. Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer. Abstract #555, American Society for Clinical Oncology (ASCO) Annual Meeting 2005.

Roche Group Media Office: Phone: +41-61-688-8888 / e-mail: basel.mediaoffice@roche.com, Baschi Dürr, Alexander Klauser, Daniel Piller (Head of Roche Group Media Office), Katja Prowald (Head of R&D Communications), Martina Rupp

Contenido patrocinado